SCHEMBL1868073

SCHEMBL1868073

O=C(O)N1CCC(n2ncc3ccc([N+](=O)[O-])cc32)CC1

nearest known ligand 0.43

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.43
HTR1A P08908 1/20 0.42
HTR1B P28222 1/20 0.42
HTR1F P30939 1/20 0.42
CYP1A2 P05177 1/20 0.41
CYP2D6 P10635 1/20 0.41
RHOA P61586 1/20 0.41
CDYL2 Q8N8U2 1/20 0.40
CDYL Q9Y232 1/20 0.40
CDY1; CDY1B Q9Y6F8 1/20 0.40
GPR119 Q8TDV5 4/20 0.39
NPC1 O15118 1/20 0.39
TDP1 Q9NUW8 2/20 0.39
KDM5A P29375 1/20 0.38
HTT P42858 2/20 0.38
LMNA P02545 2/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
GLS O94925 1/20 0.37
KDM4E B2RXH2 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1868072 1.00 L3MBTL1 (0.43) L3MBTL1HTR1AHTR1BHTR1FCYP1A2
SCHEMBL1866377 0.91 GPR119 (0.46) L3MBTL1CYP1A2CYP2D6RHOACDYL2
SCHEMBL1866375 0.91 GPR119 (0.46) L3MBTL1CYP1A2CYP2D6RHOACDYL2
SCHEMBL3388874 0.86 GLS (0.44) HTR1AHTR1BHTR1FCYP1A2RHOA
SCHEMBL29741245 0.86 GLS (0.44) HTR1AHTR1BHTR1FCYP1A2RHOA
SCHEMBL7804080 0.85 KDM4E (0.52) L3MBTL1GPR119NPC1HTTLMNA
SCHEMBL3356604 0.84 HTR1A (0.52) HTR1AHTR1BHTR1FNPC1SMN1; SMN2
SCHEMBL3352923 0.84 GPR119 (0.58) CYP1A2CYP2D6GPR119LMNA
SCHEMBL30778513 0.84 MAPT (0.46) HTR1AHTR1BHTR1FNPC1HTT
SCHEMBL3353374 0.82 ALDH1A1 (0.48) HTR1AHTR1BHTR1FCYP1A2CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9108939-B2 (1, 1, 1,3,3,3-hexafluoro-2 hydroxypropan-2-yl) phenyl derivative, pharmaceutical compositions thereof and their use for the treatment of atherosclerosis MERCK SHARP & DOHME B.V. (NL) 2015-08-18 US disclosed
EP-2493855-B1 (1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl derivatives, pharmaceutical compositions thereof and their use for the treatment of atherosclerosis MERCK SHARP & DOHME (NL) 2014-02-26 EP disclosed
US-20120238574-A1 (1, 1, 1,3,3,3 -HEXAFLUORO-2 HYDROXYPROPAN- 2 -YL) PHENYL DERIVATIVE, PHARMACEUTICAL COMPOSITIONS THEREOF AND THEIR USE FOR THE TREATMENT OF ATHEROSCLEROSIS N.V. ORGANON (NL) 2012-09-20 US disclosed
EP-2493855-A1 (1,1, 1,3, 3, 3-HEXAFLUORO-2-HYDROXYPROPAN-2-YL) PHENYL DERIVATIVES, PHARMACEUTICAL COMPOSITIONS THEREOF AND THEIR USE FOR THE TREATMENT OF ATHEROSCLEROSIS MSD Oss B.V. (NL) 2012-09-05 EP disclosed
WO-2011051282-A1 (1,1, 1,3, 3, 3-HEXAFLUORO-2-HYDROXYPROPAN-2-YL) PHENYL DERIVATIVES, PHARMACEUTICAL COMPOSITIONS THEREOF AND THEIR USE FOR THE TREATMENT OF ATHEROSCLEROSIS N.V. ORGANON (NL) 2011-05-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120238574-A1 (1, 1, 1,3,3,3 -HEXAFLUORO-2 HYDROXYPROPAN- 2 -YL) PHENYL DERIVATIVE, PHARMACEUTICAL COMPOSITIONS THEREOF AND THEIR USE FOR THE TREATMENT OF ATHEROSCLEROSIS TGFB1, FPR1, TGFB2 L3MBTL1 3951/4885HTR1A 197/4885HTR1B 228/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.